Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie

By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.

Dollar sign made of pills on blue background

Gilead Sciences Inc.’s new spin-out company to sell authorized generics of its hepatitis C fixed-dose combination products Harvoni and Epclusa was packaged as offering potential out-of-pocket savings to patients – and it could do so – but the gambit should also draw market share away from AbbVie Inc. among US government-insured patients.

Foster City, Calif.-based Gilead announced Sept. 24 that it is launching the subsidiary Asegua Therapeutics LLC to sell authorized generics...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip